GH Research PLC is a biopharmaceutical company that specializes in developing therapies for psychiatric and neurological disorders. The company's main focus is on developing inhalable and injectable 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies to treat patients with treatment-resistant depression. Their products are currently in Phase 1 and Phase 1/2 clinical trials, and preclinical development trials for other neurological and psychiatric disorders.